4.7 Review

Dysfunction of respiratory muscles in critically ill patients on the intensive care unit

Journal

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
Volume 7, Issue 4, Pages 403-412

Publisher

WILEY
DOI: 10.1002/jcsm.12108

Keywords

VIDD; Diaphragm; Weakness; Cachexia; Sepsis; Mechanical ventilation; ICU-acquired weakness; weaning failure

Funding

  1. Fresenius Kabi
  2. gsk
  3. MSD
  4. Lilly
  5. Baxter
  6. astellas
  7. AstraZeneca
  8. B. Braun
  9. CSL Behring
  10. Maquet
  11. Novartis
  12. Covidien
  13. Nycomed
  14. Pierre Fabre Pharma (RobaPharma)
  15. Pfizer
  16. Orion Pharma

Ask authors/readers for more resources

Muscular weakness and muscle wasting may often be observed in critically ill patients on intensive care units (ICUs) and may present as failure to wean from mechanical ventilation. Importantly, mounting data demonstrate that mechanical ventilation itself may induce progressive dysfunction of the main respiratory muscle, i.e. the diaphragm. The respective condition was termed ventilator-induced diaphragmatic dysfunction' (VIDD) and should be distinguished from peripheral muscular weakness as observed in ICU-acquired weakness (ICU-AW)'. Interestingly, VIDD and ICU-AW may often be observed in critically ill patients with, e.g. severe sepsis or septic shock, and recent data demonstrate that the pathophysiology of these conditions may overlap. VIDD may mainly be characterized on a histopathological level as disuse muscular atrophy, and data demonstrate increased proteolysis and decreased protein synthesis as important underlying pathomechanisms. However, atrophy alone does not explain the observed loss of muscular force. When, e.g. isolated muscle strips are examined and force is normalized for cross-sectional fibre area, the loss is disproportionally larger than would be expected by atrophy alone. Nevertheless, although the exact molecular pathways for the induction of proteolytic systems remain incompletely understood, data now suggest that VIDD may also be triggered by mechanisms including decreased diaphragmatic blood flow or increased oxidative stress. Here we provide a concise review on the available literature on respiratory muscle weakness and VIDD in the critically ill. Potential underlying pathomechanisms will be discussed before the background of current diagnostic options. Furthermore, we will elucidate and speculate on potential novel future therapeutic avenues.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available